Wellington Management Group
INZY

Wellington Management Group’s Inozyme Pharma INZY Stock Holding History

Wellington Management Group’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200,336
Closed -$555K – 1993
2024
Q4 		$555K Sell
200,336
-60,383
-23% -$230K ﹤0.01% 1819
2024
Q3 		$1.36M Buy
260,719
+27,739
+12% +$144K ﹤0.01% 1657
2024
Q2 		$1.04M Sell
232,980
-11,220
-5% -$54.4K ﹤0.01% 1661
2024
Q1 		$1.87M Buy
+244,200
New +$1.34M ﹤0.01% 1534
2021
Q4 		– Sell
-364,600
Closed -$4.23M – 2234
2021
Q3 		$4.23M Sell
364,600
-364,954
-50% -$5.69M ﹤0.01% 1543
2021
Q2 		$12.4M Buy
729,554
+261,937
+56% +$4.56M ﹤0.01% 1212
2021
Q1 		$9.26M Buy
467,617
+28,914
+7% +$638K ﹤0.01% 1260
2020
Q4 		$9.05M Buy
438,703
+134,012
+44% +$3.19M ﹤0.01% 1211
2020
Q3 		$8.01M Buy
+304,691
New +$7.57M ﹤0.01% 1160

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wellington Management Group's INZY Position: Q1 2025 in Review

Wellington Management Group sold out of Inozyme Pharma (INZY) in Q1 2025, closing a stake of 200,336 shares — an estimated $555K sold.

Wellington Management Group first reported a position in INZY in Q3 2020 and held it in 9 quarters. The position peaked at $12.4M in Q2 2021. 97 funds tracked by Wall St. Rank hold INZY as of Q1 2025.

  • Wellington Management Group reported no remaining Inozyme Pharma position as of Q1 2025 after selling out during the quarter.
  • Wellington Management Group sold 200,336 Inozyme Pharma shares in Q1 2025, an estimated $555K.
  • Wellington Management Group first reported a position in Inozyme Pharma in Q3 2020 and held it in 9 quarters.
  • Wellington Management Group's Inozyme Pharma position peaked at $12.4M in Q2 2021.
  • 97 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2025.

Based on Wellington Management Group's 13F filing for Q1 2025, filed 13 May 2025.